Figure 1.
Overview of the mevalonate pathway and the inhibition of HMG-CoA by statins.
Mevalonate pathway causes prenylation of ras, N-glycosylation of EGFR and membrane and steroidsynthesis. Statins have inhibitory effects on the mevalonate pathway and thus on prenylation of k-ras. Abbreviations: Acetyl-CoA, Acetyl coenzyme A; EGFR, epidermal growth factor receptor; FTase, farnesyltransferase; GTase, geranylgeranyltransferase; HMG-CoA (reductase), 3-hydroxy-3-methyl-glutaryl-CoA reductase; -PP, -pyrophosphate.
Table 1.
Patient Characteristics.
Figure 2.
Kaplan-Meier plots for progression free survival for patients with KRAS wild type (19 statin-users and 145 nonusers) and KRAS mutant (16 statin-users and 83 nonusers) tumors treated with capecitabine, oxaliplatin, bevacizumab and cetuximab.
Figure 3.
Kaplan-Meier plots for overall survival for patients with KRAS wild type (19 statin-users and 145 nonusers) and KRAS mutant tumors (16 statin-users and 83 nonusers) treated with capecitabine, oxaliplatin, bevacizumab and cetuximab.